

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<b>BSE Limited</b> 1 <sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>  <b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>  <b>Kind Attn.:</b> Famroze Pochara Asst. Vice President
<b>Date:</b> May 25, 2016	
<b>Re.:</b> Press Release.	


Dear Sir / Madam,


We enclose herewith a copy of press release dated May 25, 2016 under the title **Zydus receives final approval from the USFDA for Voriconazole Tablets** which will be produced at the group's formulations manufacturing facility at Baddi. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For Cadila Healthcare Limited

  
**Upen H. Shah**  
Company Secretary



Encl.: As above.

## **Zydus receives final approval from the USFDA for Voriconazole Tablets**

---

*Ahmedabad, 25 May 2016*

Zydus Cadila has received the final approval from the USFDA to market Voriconazole Tablets in strengths of 50 mg and 200 mg. The drug will be produced at the group's formulations manufacturing facility at Baddi.

The estimated sales for Voriconazole Tablets which is used in the treatment of fungal infections, is USD 92.8 million, as per IMS (*MAT March 2016*).

The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*